ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
Since Propthink’s last report on ViroPharma (VPHM), shares of the Exton, Pennsylvania-based company have risen by just under 11%. While positive returns are always welcome, ViroPharma has noticeably underperformed the NASDAQ Biotechnology Index, which has risen by over 17% in the same time frame. But, PropThink believes that ViroPharma’s past isn’t likely to repeat. Cinryze has multiple barriers to generic competition, and ViroPharma is making meaningful progress in commercializing its other drugs, as well as in moving its pipeline through the development process. At just over $25, shares of ViroPharma offer ample upside for long-term investors.